Lipomic profiling in drug discovery, development and clinical trial evaluation

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 1, 2004, Pages 112-117

  Watkins, Steven M ^a  

^a Lipomics Technologies Inc   (United States)

Author keywords

Drug development; Lipids; Lipomic profiling; Metabolism; Metabolomics

Indexed keywords

BIOLOGICAL MARKER; DRUG; LIPID; PHOSPHOLIPID; TRIACYLGLYCEROL;

CLINICAL TRIAL; DATA BASE; DISEASE COURSE; DRUG RESEARCH; HIGH THROUGHPUT SCREENING; HUMAN; LIPID METABOLISM; METABOLITE; REVIEW; ANIMAL; CHEMISTRY; DRUG DESIGN; FACTUAL DATABASE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANIMALS; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS; DATABASES, FACTUAL; DRUG DESIGN; HUMANS; LIPID METABOLISM; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS; TRIGLYCERIDES;

EID: 2942527049     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Wilson JF: Long-suffering lipids gain respect. Scientist (2003) (March 10):34-36.
2. Fitzgerald DA: Drug discovery: Lipid profiling for studying the metabolome. Genet Eng News (2001) 21 (20):32-36.
3. Han X, Gross RW: Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: A bridge to lipidomics. J Lipid Res (2003) 44(6):1071-1079. A good review of the progress to date employing ESI mass spectrometry for lipid profiling.
4. Lipids Get the Spotlight in New NIGMS 'Glue Grant': NIH News, National Institutes of Health, Bethesda, MA, USA. http://www.nih.gov/news/pr/aug2003/ nigms-11.htm
5. Dennis EA, Witztum JL: Journal of lipid research: The new era in lipid science and medicine. J Lipid Res (2003) 44(7):1267.
6. German JB, Roberts MA, Fay L, Watkins SM: Metabolomics and individual metabolic assessment: The next great challenge for nutrition. J Nutr (2002) 132(9):2486-2487.
7. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, Eckel RH, Farese RV Jr: Obesity resistance and multiple mechanisms of triglyceride synthesis In mice lacking DGAT. Nat Genet (2002) 25(1):87-90.
8. Chen HC, Smith SJ, Ladha Z, Jensen DR, Ferreira LD, Pulawa LK, McGuire JG, Pitas RE, Eckel RH, Farese RV Jr: Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest (2002) 109(8):1049-1055.
9. Buhman KK, Smith SJ, Stone SJ, Repa JJ, Wong JS, Knapp FF Jr, Hamilton RL, Abumrad NA, Farese RV: DGAT1 is not essential for Intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem (2002) 277(28):25474-25479.
10. Ludwig EH, Mahley RW, Palaoglu E, Ozbayrakci S, Balestra ME, Borecki IB, Innerarity TL, Farese RV Jr: DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women. Clin Genet (2003) 62(1):68-73.
11. Chen HC, Jensen DR, Myers HM, Eckel RH, Farese RV Jr: Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest (2003) 111(11):1715-1722.
12. Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold KR, Elias PM, Farese RV Jr: Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem (2003): epub ahead of print 10.1074/jbc.M311000200.
13. Wakimoto K, Chiba H, Michibata H, Seishima M, Kawasaki S. Okubo K, Mitsui H, Torii H, Imai Y: A novel diacylglycerol acyltransferase (DGAT2) is decreased in human psoriatic skin and increased in diabetic mice. Biochem Biophys Res Commun (2003) 310(2):296-302.
14. Walkey CJ, Donohue LR, Bronson R, Agellon LB, Vance DE: Disruption of the murine gene encoding phosphatidylethanolamine N-methyltransferase. Proc Natl Acad Sci USA (1997) 94(24):12880-12885.
15. Nishimaki-Mogami T, Yao Z, Fujimori K: Inhibition of phosphatidylcholine synthesis via the phosphatidylethanolamine methylation pathway impairs incorporation of bulk lipids in VLDL in cultured rat hepatocytes. J Lipid Res (2002) 43(7):1035-1045.
16. Noga AA, Zhao Y, Vance DE: An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem (2002) 277(44):42358-42365.
17. Zhu X, Song J, Mar MH, Edwards LJ, Zeisel SH: Phosphatidylethanolamine N-methyltransferase (PEMT) knockout mice have hepatic steatosis and abnormal hepatic choline metabolite concentrations despite ingesting a recommended dietary intake of choline. Biochem J (2003) 370(Pt 3):987-993.
18. Sehayek E, Wang R, Ono JG, Zinchuk VS, Duncan EM, Shefer S, Vance DE, Ananthananrayanan M, Chait BT, Breslow JL: Localization of the PE methylation pathway and SR-BI to the canalicular membrane: Evidence for apical PC biosynthesis that may promote biliary excretion of phospholipid and cholesterol. J Lipid Res (2003) 44(9):1605-1613.
19. Watkins SM, Zhu X, Zeisel SH: Phosphatidylethanolamine-N- methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. J Nutr (2003) 133(11):3386-3391. This manuscript uses lipomic profiling to describe the effects of nutrition on a PEMT-deficient mouse strain. The effects of PEMT and choline status on hepatic and plasma lipid metabolism are described.
20. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH: Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone. J Lipid Res (2002) 43(11):1809-1817. The first report describing the use of quantitative metabolite profiling to identify the specific effects of a drug on lipid metabolism.
21. Avery EL, Dunstan RH, Neil JA: The use of lipid metabolite profiling to assess the biological impact of marine sewage pollution. Arch Environ Contam Toxicol (1998) 35(2):229-235.
22. Stanton B, Watkins S, German JB, Lasely B: Interaction of estrogen and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) with hepatic fatty acid synthesis and metabolism of male chickens (Gallus domesticus). Comp Biochem Physiol C Toxicol Pharmacol (2001) 129(2):137-150.
23. Moran FM, Hendrickx AG, Shideler S, Overstreet JW, Watkins SM, Lastey BL: Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on fatty acid availability and neural tube formation in cynomolgus macaque, Macaca fascicularis. Birth Defects Res Part B Dev Reprod Toxicol (2004): in press.
24. Pruzanski W, Stefanski E, de Beer FC, de Beer MC, Ravandi A, Kuksis A: Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J Lipid Res (2000) 41(7):1035-1047. An excellent example of lipid profiling of relevance to human pathology. A comprehensive lipid composition of acute-phase and normal HDL particles is described.
25. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Aterioscler Thromb Vasc Biol (2002) 22(7):1175-1180.
26. Blake GJ, Otvos JD, Rifai N, Ridker PM: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation (2002) 106(15):1930-1937.
27. 6-desaturase deficiency in human skin fibroblasts. J Lipid Res (2001) 42(4):501-508. Describes the identification of a patient's specific metabolic defect using cultured fibroblasts and a focused form of lipid profiling.